Do you take medicine for high cholesterol? If so, you may also be suffering from fatty liver and potentially nonalcoholic steatohepatitis (NASH), which are clinically silent disease processes. If you would like to learn more about fatty liver and nonalcoholic fatty liver/NASH.
The National Institutes of Health has declared fatty liver the next healthcare crisis in America. It is estimated that 25% of the United States population, or close to 85 million people, unknowingly suffer from non-alcoholic fatty liver disease. This entity is related to poor diet, the obesity crisis in America, and the lack of exercise with an increasingly sedentary population. Fatty liver disease is now the most common reason for liver transplantation in the world, including in the United States, surpassing Hepatitis B, Hepatitis C and alcoholic/hepatitis.
Approximately 15 to 20% of people with fatty liver will progress to non-alcoholic steatohepatitis (non-alcoholic fatty liver) (NASH). NASH is defined as inflammation of the liver which subsequently progresses to fibrosis and end-stage liver disease with cirrhosis. When this occurs, death often ensues quickly thereafter. Fatty liver and NASH are clinically silent diseases. Typically, they are discovered on routine physical examination as a result of abnormally increased liver function tests. There is an increased incidence of fatty liver in diabetic patients, both Type I and Type II Diabetes Mellitus. In addition, there is an increased progression of fatty liver disease to NASH in the Hispanic and Asian populations.
Up to now, the only way to diagnose NASH was with a liver biopsy, an invasive and potentially risky procedure which entails putting a large needle into the liver and obtaining core specimens of the liver. There is now a new non-invasive MRI technique which allows for delineation of fat content within the liver, iron content within the liver, and the presence of inflammation and fibrosis within the liver. This new sophisticated software platform is known as the LiverMultiScan Discover™. It entails only a 15 minute non-contrast MRI of the abdomen, providing clinical information which is unavailable through any other non-invasive manner. The only other way to obtain this clinical information is with an invasive and potentially dangerous liver biopsy.
Currently, there is no cure for NASH. Once a patient is diagnosed with NASH, increasing deterioration of liver function eventually leading to liver failure and demise of the patient occurs. There are currently multiple new drugs being tested in the research pipeline which offer the opportunity to halt the progression of NASH and allow the liver to actually regenerate itself into a normal organ. These drugs in the research pipeline have the potential to prevent liver failure, cirrhosis and death as a result of NASH.
At NASH Health Initiative, we are harnessing the power of this new non-contrast MRI examination to identify those patients who may be at significant risk for non alcoholic fatty liver/NASH or have NASH and may derive significant benefit from the research opportunities currently available in the United States.
There are multiple NASH trials currently ongoing in your community. With integrity and transparency, our goal is to progress the science of fatty liver and nonalcoholic fatty liver/NASH and ensure that those people who have no other treatment options have the access to potentially life-saving therapy.
If you or a loved one would like more information about fatty liver or nonalcoholic fatty liver/NASH, we encourage you to contact us at firstname.lastname@example.org or call 407.902.9486.
Nash: Hope of the Future
Stephen M. Bravo, MD and CEO, was named one of Orlando’s best doctors by Best Doctors in America and Consumer’s Guide to Top Doctors 2011-2020, as highlighted in Orlando Magazine’s Annual Best Physicians List.
Dr. Bravo received a BA in Biology graduating magna cum laude from Harvard University. He is a graduate of the Cornell University Medical College, performed his internship at Yale-New Haven Hospital, performed diagnostic radiology residency and was Chief Resident at the Brigham and Women's Hospital-Harvard Medical School. He performed his fellowships in Neuroradiology and Cardiovascular and Interventional Radiology at BWH, Dana Farber Cancer Institute and the Boston Children's Hospital. He is board certified by the American Board of Radiology and is a former attending radiologist at Brigham and Women’s Hospital. He is also a former faculty member at Harvard Medical School. He is an expert in neuroradiology, musculoskeletal radiology, and interventional radiology, and has authored numerous publications and abstracts in these areas of subspecializations. In addition, he also has been the principal investigator or co-investigator in over 200 pharmaceutical research trials; with research interest being nutrition, fatty liver/NASH, neurodegenerative disease, osteoarthritis, and concussions. He also has scientific contributions focusing on diet and metabolic syndrome, published in the Journal of Obesity, and has most recently lectured in the area of noninvasive diagnosis of NASH with his paper " Evaluation of Multiparametric MRI in Comparison with MR Elastography in Patients Evaluated for Chronic Liver Disease" presented at the International Liver Congress Meeting of the European Association for the Study of the Liver (EASL) in Paris April 2018.
Dr. Stephen Bravo has partnered with the Perspectum Diagnostics' imaging team consisting of specialists with 25+ years in Healthcare technological advancement leading global teams at Microsoft, GE Healthcare, Nellcor and Misys Healthcare delivering innovative solutions spanning imaging, direct to consumer, medical device and healthcare IT solutions. This company has the patent and exclusive rights to the LiverMultiScan Discover™ software.
You can rely on us to treat all of your chronic care needs such as hypertension, diabetes, elevated cholesterol, and others.
“NASH: Hope for the Future” and “Living with NASH” from the American Liver Foundation.
Disclaimer: Links are provided for your information and no endorsement should be inferred therefrom.
Powered by GoDaddy Website Builder